德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene Appoints Amily Zhang as its Chief Medical Officer 2022-12-08 08:30
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence 2022-09-14 08:30
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022-04-11 08:30
Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day 2021-11-19 13:00
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections 2021-07-26 08:44
Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development 2021-05-25 08:00
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines 2021-05-06 11:28
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment 2021-04-29 08:34
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL 2021-04-13 08:00
Antengene Appoints Kevin Lynch as Chief Medical Officer 2021-03-25 23:26
Antengene Appoints Bo Shan as Chief Scientific Officer 2021-03-25 22:36
Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021 2021-03-22 08:00
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea 2021-03-15 08:00
Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference 2021-01-11 07:26
Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines 2020-10-15 08:59
Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer 2020-10-12 20:00
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization 2020-07-20 08:00
Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development 2020-07-13 06:00
­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions 2020-07-02 08:16
Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer 2020-06-08 20:00
1 2